Bárbara B. Garrido-Suárez
Research Subjects
Bárbara B. Garrido-Suárez has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Gabino Garrido
Departamento de Ciencias Farmacéuticas, Facultad de Ciencias, Edificio Ñ3, Universidad Católica del Norte, Angamos, 0610, Antofagasta, Chile
7 shared publications Fe Bosch
3 shared publicationsNelson Merino
Laboratorio de Farmacología y Toxicología, Centro de Investigación y Desarrollo de Medicamentos, Ave. 26 No. 1605, Nuevo Vedado, Havana, Cuba
3 shared publications- René Delgado
Clinical Pharmacy and Pharmaceutical Care Unit, Department of Pharmacy and Pharmaceutical Technology, and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain
3 shared publications María del C. Rabí
2 shared publicationsOdalys Valdés
Laboratorio de Farmacología y Toxicología, Centro de Investigación y Desarrollo de Medicamentos, Ave. 26 No. 1605, Nuevo Vedado, Havana, Cuba
2 shared publications
Latest Publications
- 20 June 2022
- Published by Elsevier in Sleep Medicine
- Vol. 98, 79-86
Reactogenic sleepiness after COVID-19 vaccination. A hypothesis involving orexinergic system linked to inflammatory signals
- 20 June 2022
- Published by Elsevier in Sleep Medicine
- Vol. 98, 79-86
Reactogenic sleepiness after COVID-19 vaccination. A hypothesis involving orexinergic system linked to inflammatory signals
- 1 November 2021
- Published by Elsevier in Neurochemistry International
- Vol. 150, 105160
Synergistic interaction between amitriptyline and paracetamol in persistent and neuropathic pain models: An isobolografic analysis
- 1 November 2021
- Published by Elsevier in Neurochemistry International
- Vol. 150, 105160
Synergistic interaction between amitriptyline and paracetamol in persistent and neuropathic pain models: An isobolografic analysis
- 1 December 2020
- Published by Elsevier in Brain Research Bulletin
- Vol. 165, 185-197
Anti-hypernociceptive and anti-inflammatory effects of JM-20: A novel hybrid neuroprotective compound
- 1 December 2020
- Published by Elsevier in Brain Research Bulletin
- Vol. 165, 185-197
Anti-hypernociceptive and anti-inflammatory effects of JM-20: A novel hybrid neuroprotective compound
- 22 November 2019
- Published by Wiley in Phytotherapy Research
- Vol. 34 (3) , 505-525
Mangiferin: Possible uses in the prevention and treatment of mixed osteoarthritic pain
Osteoarthritis (OA) pain has been proposed to be a mixed pain state, because in some patients, central nervous system factors are superimposed upon the more traditional peripheral factors. In addition, a considerable amount of preclinical and clinical evidence has shown that, accompanying the central neuroplasticity changes and partially driven by a peripheral nociceptive input, a real neuropathic component occurs that are particularly linked to disease severity and progression. Hence, innovative strategies targeting neuroprotection and particularly neuroinflammation to prevent and treat OA pain could be introduced. Mangiferin (MG) is a glucosylxanthone that is broadly distributed in higher plants, such asMangifera indicaL. Previous studies have documented its analgesic, anti‐inflammatory, antioxidant, neuroprotective, and immunomodulatory properties. In this paper, we propose its potential utility as a multitargeted compound for mixed OA pain, even in the context of multimodal pharmacotherapy. This hypothesis is supported by three main aspects: the cumulus of preclinical evidence around this xanthone, some preliminary clinical results using formulations containing MG in clinical musculoskeletal or neuropathic pain, and by speculations regarding its possible mechanism of action according to recent advances in OA pain knowledge.
- 22 November 2019
- Published by Wiley in Phytotherapy Research
- Vol. 34 (3) , 505-525
Mangiferin: Possible uses in the prevention and treatment of mixed osteoarthritic pain
Osteoarthritis (OA) pain has been proposed to be a mixed pain state, because in some patients, central nervous system factors are superimposed upon the more traditional peripheral factors. In addition, a considerable amount of preclinical and clinical evidence has shown that, accompanying the central neuroplasticity changes and partially driven by a peripheral nociceptive input, a real neuropathic component occurs that are particularly linked to disease severity and progression. Hence, innovative strategies targeting neuroprotection and particularly neuroinflammation to prevent and treat OA pain could be introduced. Mangiferin (MG) is a glucosylxanthone that is broadly distributed in higher plants, such asMangifera indicaL. Previous studies have documented its analgesic, anti‐inflammatory, antioxidant, neuroprotective, and immunomodulatory properties. In this paper, we propose its potential utility as a multitargeted compound for mixed OA pain, even in the context of multimodal pharmacotherapy. This hypothesis is supported by three main aspects: the cumulus of preclinical evidence around this xanthone, some preliminary clinical results using formulations containing MG in clinical musculoskeletal or neuropathic pain, and by speculations regarding its possible mechanism of action according to recent advances in OA pain knowledge.
- 1 January 2011
- Published by S. Karger AG in Research in Complementary Medicine
- Vol. 18 (6) , 345-350
Case Series in Patients with Zoster-Associated Pain Using Mangifera indica L. Extract
Neuroimmune activation has been proposed as a source of new targets for therapeutic intervention in neuropathic pain. Vimang® is an aqueous extract from Mangifera indica L. (common mango) that is traditionally used in Cuba for its antioxidant, anti-inflammatory, analgesic, and immunomodulatory properties. In the present case report, we determine its potential effects in patients with zoster-associated pain. 12 patients with zoster-associated pain (6 with subacute herpetic neuralgia and 6 with post-herpetic neuralgia) received a daily dose of 1,800 mg of extract (2 coated 300 mg tablets, 3 times daily before meals) together with low doses of amitriptyline (10-25 mg/day) for 120 days. In addition to the tablets, patients used Vimang® cream 1.2% as a topical agent. The average daily pain score using the Likert scale, area and rate of dynamic allodynia, rate of thermal allodynia, and frequency of burning spontaneous pain were evaluated. Pain scores and sensory abnormalities decreased significantly (p < 0.05) with respect to baseline data from week 4. No adverse events were reported. These results suggest that Vimang® could be beneficial in the treatment of neuropathic pain. However, a controlled clinical trial is necessary to confirm this hypothesis.
- 1 January 2011
- Published by S. Karger AG in Research in Complementary Medicine
- Vol. 18 (6) , 345-350
Case Series in Patients with Zoster-Associated Pain Using Mangifera indica L. Extract
Neuroimmune activation has been proposed as a source of new targets for therapeutic intervention in neuropathic pain. Vimang® is an aqueous extract from Mangifera indica L. (common mango) that is traditionally used in Cuba for its antioxidant, anti-inflammatory, analgesic, and immunomodulatory properties. In the present case report, we determine its potential effects in patients with zoster-associated pain. 12 patients with zoster-associated pain (6 with subacute herpetic neuralgia and 6 with post-herpetic neuralgia) received a daily dose of 1,800 mg of extract (2 coated 300 mg tablets, 3 times daily before meals) together with low doses of amitriptyline (10-25 mg/day) for 120 days. In addition to the tablets, patients used Vimang® cream 1.2% as a topical agent. The average daily pain score using the Likert scale, area and rate of dynamic allodynia, rate of thermal allodynia, and frequency of burning spontaneous pain were evaluated. Pain scores and sensory abnormalities decreased significantly (p < 0.05) with respect to baseline data from week 4. No adverse events were reported. These results suggest that Vimang® could be beneficial in the treatment of neuropathic pain. However, a controlled clinical trial is necessary to confirm this hypothesis.
- Open Access
A Mangifera indica L. Extract Could Be Used to Treat Neuropathic Pain and Implication of Mangiferin
It has been accepted that neuroinflammation, oxidative stress and glial activation are involved in the central sensitization underlying neuropathic pain. Vimang is an aqueous extract of Mangifera indica L. traditionally used in Cuba for its analgesic, anti-inflammatory, antioxidant and immunomodulatory properties. Several formulations are available, and also for mangiferin, its major component. Preclinical studies demonstrated that these products prevented tumor necrosis factor α -induced IκB degradation and the binding of nuclear factor κB to DNA, which induces the transcription of genes implicated in the expression of some mediators and enzymes involved in inflammation, pain, oxidative stress and synaptic plasticity. In this paper we propose its potential utility in the neuropathic pain treatment. This hypothesis is supported in the cumulus of preclinical and clinical evidence around the extract and mangiferin, its major component, and speculates about the possible mechanism of action according to recent advances in the physiopathology of neuropathic pain.
Open AccessA Mangifera indica L. Extract Could Be Used to Treat Neuropathic Pain and Implication of Mangiferin
It has been accepted that neuroinflammation, oxidative stress and glial activation are involved in the central sensitization underlying neuropathic pain. Vimang is an aqueous extract of Mangifera indica L. traditionally used in Cuba for its analgesic, anti-inflammatory, antioxidant and immunomodulatory properties. Several formulations are available, and also for mangiferin, its major component. Preclinical studies demonstrated that these products prevented tumor necrosis factor α -induced IκB degradation and the binding of nuclear factor κB to DNA, which induces the transcription of genes implicated in the expression of some mediators and enzymes involved in inflammation, pain, oxidative stress and synaptic plasticity. In this paper we propose its potential utility in the neuropathic pain treatment. This hypothesis is supported in the cumulus of preclinical and clinical evidence around the extract and mangiferin, its major component, and speculates about the possible mechanism of action according to recent advances in the physiopathology of neuropathic pain.
- 14 August 2009
- Published by Elsevier in Brain Research Bulletin
- Vol. 79 (6) , 339-344
Pre-emptive anti-hyperalgesic effect of electroacupuncture in carrageenan-induced inflammation: Role of nitric oxide
- 14 August 2009
- Published by Elsevier in Brain Research Bulletin
- Vol. 79 (6) , 339-344
Pre-emptive anti-hyperalgesic effect of electroacupuncture in carrageenan-induced inflammation: Role of nitric oxide